We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AstraZeneca has signed a deal with Grünenthal worth up to $922 million in which the latter will acquire the regional rights to two of the pharma giant’s drugs.